PIVOTAL trial delivers significant results for haemodialysis patients

The results of the four-and-a-half year PIVOTAL clinical trial to determine how much intravenous iron could safely be given to kidney patients on haemodialysis, were revealed at the 2018 ASN Kidney Week conference in San Diego during the high- impact clinical trials session. The results were also published online in the New England Journal of Medicine.


The trial compared proactive, high-dose and reactive low-dose intravenous iron regimens for patients in their first year on haemodialysis.


Main findings:

The trial demonstrated no evidence of harm with the proactive high-dose strategy – with no increased risk of death, heart failure or infection.

View the full update here